Blueprint Medicines Co. (NASDAQ:BPMC) to Post Q2 2026 Earnings of $0.33 Per Share, Zacks Research Forecasts

Blueprint Medicines Co. (NASDAQ:BPMC) – Analysts at Zacks Research lifted their Q2 2026 EPS estimates for shares of Blueprint Medicines in a report released on Monday, September 16th. Zacks Research analyst A. Chakraborty now expects that the biotechnology company will post earnings per share of $0.33 for the quarter, up from their prior estimate of $0.31. The consensus estimate for Blueprint Medicines’ current full-year earnings is ($3.99) per share.

Several other brokerages also recently issued reports on BPMC. Needham & Company LLC reissued a “buy” rating and set a $130.00 price objective on shares of Blueprint Medicines in a research report on Thursday, August 1st. Barclays increased their price objective on Blueprint Medicines from $75.00 to $105.00 and gave the stock an “equal weight” rating in a research report on Monday, July 29th. Oppenheimer increased their price target on Blueprint Medicines from $114.00 to $125.00 and gave the stock an “outperform” rating in a report on Monday, July 8th. Morgan Stanley boosted their price objective on shares of Blueprint Medicines from $110.00 to $115.00 and gave the company an “equal weight” rating in a research note on Friday, July 12th. Finally, Robert W. Baird lifted their price objective on Blueprint Medicines from $112.00 to $127.00 and gave the company an “outperform” rating in a report on Friday, August 2nd. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, eleven have issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $120.00.

Blueprint Medicines Price Performance

BPMC stock opened at $91.68 on Thursday. The company has a current ratio of 3.71, a quick ratio of 3.65 and a debt-to-equity ratio of 1.06. The company has a market capitalization of $5.74 billion, a P/E ratio of -19.06 and a beta of 0.58. The business has a 50 day simple moving average of $98.29 and a 200-day simple moving average of $98.96. Blueprint Medicines has a twelve month low of $43.89 and a twelve month high of $121.90.

Blueprint Medicines (NASDAQ:BPMC) last posted its earnings results on Thursday, August 1st. The biotechnology company reported ($0.80) earnings per share for the quarter, topping the consensus estimate of ($1.29) by $0.49. Blueprint Medicines had a negative return on equity of 157.30% and a negative net margin of 56.64%. The firm had revenue of $138.20 million during the quarter, compared to analysts’ expectations of $104.02 million. During the same quarter in the previous year, the business earned ($2.19) earnings per share. The firm’s revenue was up 139.9% compared to the same quarter last year.

Insider Buying and Selling

In other news, insider Philina Lee sold 41,913 shares of the business’s stock in a transaction that occurred on Monday, August 5th. The stock was sold at an average price of $93.19, for a total value of $3,905,872.47. Following the completion of the sale, the insider now directly owns 34,729 shares in the company, valued at approximately $3,236,395.51. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other news, insider Debra Durso-Bumpus sold 8,817 shares of the company’s stock in a transaction dated Wednesday, July 3rd. The shares were sold at an average price of $111.29, for a total transaction of $981,243.93. Following the completion of the transaction, the insider now owns 43,763 shares in the company, valued at $4,870,384.27. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Philina Lee sold 41,913 shares of the business’s stock in a transaction that occurred on Monday, August 5th. The stock was sold at an average price of $93.19, for a total value of $3,905,872.47. Following the transaction, the insider now owns 34,729 shares of the company’s stock, valued at $3,236,395.51. The disclosure for this sale can be found here. Over the last three months, insiders sold 54,913 shares of company stock worth $5,352,249. Corporate insiders own 4.21% of the company’s stock.

Institutional Investors Weigh In On Blueprint Medicines

Hedge funds and other institutional investors have recently modified their holdings of the stock. Gilbert & Cook Inc. raised its holdings in shares of Blueprint Medicines by 8.5% in the 4th quarter. Gilbert & Cook Inc. now owns 4,846 shares of the biotechnology company’s stock worth $447,000 after purchasing an additional 380 shares in the last quarter. Principal Financial Group Inc. raised its position in shares of Blueprint Medicines by 1.7% during the fourth quarter. Principal Financial Group Inc. now owns 14,510 shares of the biotechnology company’s stock worth $1,338,000 after purchasing an additional 247 shares during the period. Vanguard Personalized Indexing Management LLC purchased a new stake in shares of Blueprint Medicines during the fourth quarter valued at $321,000. Norges Bank acquired a new position in shares of Blueprint Medicines in the 4th quarter valued at $55,893,000. Finally, BI Asset Management Fondsmaeglerselskab A S purchased a new position in Blueprint Medicines in the 4th quarter worth about $95,000.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.